Bolt Biotherapeutics (BOLT) vs Longeveron (LGVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($7.9 million vs $7.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLT | LGVN |
|---|---|---|
| Share price | $4.11 | $2.48 |
| Market cap | $7.92M | $7.91M |
| 1-day change | +13.22% | +4.64% |
| EPS (TTM) | $-16.51 | $-9.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.20 | $12.30 |
| 52-week low | $3.10 | $2.30 |
| Distance from 52-week high | -42.92% | -79.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +605.60% | +2369.76% |
| Average volume | 26.26K | 92.38K |
| Shares outstanding | 1.93M | 3.04M |
| Employees | 23 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
BOLT vs LGVN FAQ
Which is bigger, Bolt Biotherapeutics or Longeveron?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $7.92M compared with $7.91M for Longeveron (LGVN).
Are Bolt Biotherapeutics and Longeveron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.